AZ selects ImpactRx to check effectiveness
execute their plan of action; how well physicians perceive their efforts; and the impact of their activities on new patient treatment decisions.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.